Phendimetrazine Shortage: What Providers and Prescribers Need to Know in 2026

Phendimetrazine (formerly Bontril) is a Schedule III sympathomimetic amine anorectic that has been FDA-approved since 1976. While it remains a viable short-term adjunct for weight management in appropriate patients, prescribers in 2026 are increasingly encountering a practical problem: patients who receive a valid prescription are struggling to find it at their pharmacy.

This article provides a clinically focused update on Phendimetrazine supply challenges, the structural factors driving them, and practical guidance for prescribers managing patients on or being considered for this medication.

Current Supply Status (2026)

As of early 2026, Phendimetrazine is not on the FDA's Drug Shortage Database. Manufacturers are reporting adequate production of both the 35 mg immediate-release tablets and 105 mg extended-release capsules. However, distribution-level availability remains inconsistent, particularly at large chain pharmacies.

The practical implication for prescribers: a valid prescription does not guarantee timely access. Patients may need to contact multiple pharmacies before finding Phendimetrazine in stock, which creates adherence risks and patient frustration.

Root Causes of Phendimetrazine Unavailability

1. DEA Schedule III Production Quotas

As a Schedule III controlled substance, Phendimetrazine production is subject to annual DEA aggregate production quotas (APQs). Unlike Schedule IV substances such as phentermine — which has a larger, better-documented demand profile — Phendimetrazine's quotas may not scale quickly enough to meet shifting demand. Quota increases require formal applications that can take months to years to be granted.

2. Brand Discontinuation and Limited Generic Manufacturers

Bontril PDM and Bontril Slow Release — the two brand-name formulations — have been discontinued in the U.S. market. The generic market is served by a limited number of manufacturers (including Glenmark and Nucare), creating concentration risk. Manufacturing disruptions at a single facility can meaningfully impact national supply.

3. Rising Demand for Oral Weight-Loss Medications

The GLP-1 era has driven unprecedented public attention to weight-loss pharmacotherapy. Patients who cannot access or afford GLP-1 medications are seeking alternatives, including older oral agents like Phendimetrazine. This demand increase has not been matched by equivalent DEA quota expansion.

4. Chain Pharmacy Inventory Practices

Large chain pharmacies rely on automated demand-forecasting inventory systems. Phendimetrazine's relatively niche patient population means it is not routinely stocked at high volumes at most chain locations. When local demand increases — even modestly — automated systems may be slow to trigger reorders. Independent pharmacies, which often order manually based on patient relationships, tend to stock Phendimetrazine more reliably.

Clinical Implications and Prescribing Considerations

Given the current supply landscape, the following clinical approaches are recommended:

• Verify pharmacy availability before writing the prescription: Direct patients to call an independent pharmacy or use a pharmacy-checking service before picking up their prescription. This prevents unnecessary delays and patient frustration.
• Set expectations at the time of prescribing: Inform patients that Phendimetrazine may not be available at every pharmacy and that they may need to call ahead or visit an independent pharmacy.
• Document insurance step therapy requirements proactively: Many insurance plans that cover weight-loss medications require step therapy starting with phentermine. If you're prescribing Phendimetrazine, documenting any prior trials of phentermine (or clinical rationale for bypassing it) can streamline prior authorizations.
• Consider whether the ER or IR formulation is more appropriate: The 105 mg ER capsule (once daily) may improve adherence. Both formulations are equivalent in therapeutic value; specifying one over the other based on what your patient's pharmacy stocks can reduce back-and-forth.

Prescribing Alternatives When Phendimetrazine Is Unavailable

When Phendimetrazine cannot be consistently sourced, the following pharmacological alternatives are worth discussing with appropriate patients:

• Phentermine (Schedule IV): Most widely available and prescribed anorectic in the U.S. Works through a similar norepinephrine-releasing mechanism. Generally preferred when availability is a concern.
• Phentermine/topiramate ER (Qsymia, Schedule IV): Approved for chronic weight management. Generic available. Higher efficacy profile; requires REMS program counseling for women of reproductive potential (teratogenicity risk with topiramate).
• Naltrexone/bupropion (Contrave): Non-controlled, non-stimulant. Appropriate for patients with CVD contraindications to stimulants, history of anxiety, or those who cannot use controlled substances.
• GLP-1 receptor agonists (semaglutide, tirzepatide): Superior long-term efficacy, particularly for patients with significant obesity (BMI ≥30) or metabolic comorbidities. Injectable; cost is a barrier for many patients.

Tools for Providers: Checking Pharmacy Stock for Your Patients

medfinder for Providers (medfinder.com/providers) allows prescribers to verify which pharmacies near their patient have Phendimetrazine in stock before writing the prescription. This reduces the likelihood of a patient leaving with a prescription they can't fill and ensures your clinical efforts translate into completed treatment.